Analysis of the duration of efficacy and influencing factors of rasagiline (Azila)

Rasagiline (Rasagiline) is a monoamine oxidase-B (MAO-B) inhibitor. It is mainly used for the early treatment of Parkinson's disease or in combination with levodopa to improve motor symptoms and delay the progression of the disease. Its mechanism of action is to inhibit the decomposition of dopamine in the brain and increase dopamine levels, thereby improving the patient's motor function. Regarding the duration of efficacy, clinical studies have shown that when rasagiline is used as a single agent in the treatment of early-stage Parkinson's disease, its efficacy can last from weeks to months, and is closely related to the patient's disease duration, severity of underlying symptoms, and medication compliance.

In patients with early-stage Parkinson's disease, rasagiline often shows sustained improvement in motor symptoms. According to clinical trial data, patients treated with early monotherapy can observe improvements in exercise capacity after taking the drug for 4 to 12 weeks, and the efficacy can be maintained stable for 6 to 12 months of continued use. The efficacy is mainly reflected in reducing tremor, stiffness, bradykinesia and improving the ability to perform daily activities. However, for patients with advanced stages or severe symptoms, the efficacy of a single drug may be limited and requires combined treatment with levodopa or other anti-Parkinson drugs.

There are many factors that affect the duration of the therapeutic effect of rasagiline, including patient age, disease duration, and severity of basic motor symptoms. Elderly patients or those with a longer course of disease have more severe neuronal damage, and the effect of the drug may not be as obvious as in early-stage patients. In addition, medication compliance is also an important factor. If the patient misses a dose or adjusts the dosage improperly, the efficacy may decline prematurely. Combination regimens, individual differences, and comorbidities also influence the duration of efficacy.

To sum up, the therapeutic effect of rasagiline can usually last from several weeks to months or even more than a year , but the specific effect will vary depending on individual patient differences. In order to maintain the best efficacy, patients need to strictly follow the doctor's prescription and take medication regularly, and at the same time regularly follow up and evaluate motor symptoms, and timely adjust the treatment plan according to changes in the condition to achieve long-term stable symptom control and improvement in quality of life.

Reference link:https://www.drugs.com